438 related articles for article (PubMed ID: 24341898)
1. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.
Aissa Larousse J; Trimoulet P; Recordon Pinson P; Tauzin B; Azzouz MM; Ben Mami N; Cheikh I; Triki H; Fleury H
Virol J; 2015 Jun; 12():84. PubMed ID: 26047611
[TBL] [Abstract][Full Text] [Related]
3. Naturally occurring HCV NS5A/B inhibitor resistance-associated mutations to direct-acting antivirals.
Nguyen LT; Hall N; Sheerin D; Carr M; De Gascun CF;
Antivir Ther; 2016; 21(5):447-53. PubMed ID: 26789637
[TBL] [Abstract][Full Text] [Related]
4. Resistance-associated variants in HCV subtypes 1a and 1b detected by Ion Torrent sequencing platform.
Gaspareto KV; Ribeiro RM; de Mello Malta F; Gomes-Gouvêa MS; Muto NH; Romano CM; Mendes-Correa MC; Carrilho FJ; Sabino EC; Rebello Pinho JR
Antivir Ther; 2016; 21(8):653-660. PubMed ID: 27314166
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
6. NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus.
Peres-da-Silva A; de Almeida AJ; Lampe E
J Antimicrob Chemother; 2015 Mar; 70(3):726-30. PubMed ID: 25414201
[TBL] [Abstract][Full Text] [Related]
7. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.
Costantino A; Spada E; Equestre M; Bruni R; Tritarelli E; Coppola N; Sagnelli C; Sagnelli E; Ciccaglione AR
Virol J; 2015 Nov; 12():186. PubMed ID: 26577836
[TBL] [Abstract][Full Text] [Related]
8. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.
Margeridon-Thermet S; Le Pogam S; Li L; Liu TF; Shulman N; Shafer RW; Najera I
PLoS One; 2014; 9(8):e105569. PubMed ID: 25140696
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
[TBL] [Abstract][Full Text] [Related]
10. Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.
Li Z; Zhang Y; Liu Y; Shao X; Luo Q; Cai Q; Zhao Z
Medicine (Baltimore); 2017 May; 96(19):e6830. PubMed ID: 28489763
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.
Malta F; Gaspareto KV; Lisboa-Neto G; Carrilho FJ; Mendes-Correa MC; Pinho JRR
BMC Infect Dis; 2017 Nov; 17(1):716. PubMed ID: 29132303
[TBL] [Abstract][Full Text] [Related]
12. Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) at baseline of treatment in thalassemia patients: a referral center study.
Safarnezhad Tameshkel F; Karbalaie Niya MH; Zamani F; Motamed N; Ajdarkosh H; Vafaeimanesh J; Khoonsari M; Sohrabi MR; Aten S; Azarkeivan A; Eslami MS; Perumal D; Maadi M; Ghanbari B; Keyvani H
Arch Virol; 2020 Oct; 165(10):2193-2203. PubMed ID: 32638116
[TBL] [Abstract][Full Text] [Related]
13. Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.
Dietz J; Susser S; Berkowski C; Perner D; Zeuzem S; Sarrazin C
PLoS One; 2015; 10(8):e0134395. PubMed ID: 26317755
[TBL] [Abstract][Full Text] [Related]
14. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank.
Alves R; Queiroz AT; Pessoa MG; da Silva EF; Mazo DF; Carrilho FJ; Carvalho-Filho RJ; de Carvalho IM
J Viral Hepat; 2013 Jun; 20(6):414-21. PubMed ID: 23647958
[TBL] [Abstract][Full Text] [Related]
15. Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients.
Li Z; Liu Y; Zhang Y; Shao X; Luo Q; Guo X; Lin G; Cai Q; Zhao Z; Chong Y
Biomed Res Int; 2017; 2017():9849823. PubMed ID: 29164151
[TBL] [Abstract][Full Text] [Related]
16. Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV.
Noble CF; Malta F; Lisboa-Neto G; Gomes-Gouvêa MS; Leite AGB; de Castro VFD; Santana RAF; Carrilho FJ; Mendes-Correa MC; Pinho JRR
Arch Virol; 2017 Jan; 162(1):165-169. PubMed ID: 27704215
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina.
Martínez AP; García G; Ridruejo E; Culasso AC; Pérez PS; Pereson MJ; Neukam K; Flichman D; Di Lello FA
J Med Virol; 2019 Nov; 91(11):1970-1978. PubMed ID: 31273794
[TBL] [Abstract][Full Text] [Related]
18. Development and persistence of DAA resistance associated mutations in patients failing HCV treatment.
Paolucci S; Fiorina L; Mariani B; Landini V; Gulminetti R; Novati S; Maserati R; Barbarini G; Bruno R; Baldanti F
J Clin Virol; 2015 Nov; 72():114-8. PubMed ID: 26489401
[TBL] [Abstract][Full Text] [Related]
19. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population.
Ramezani A; Baesi K; Banifazl M; Mohraz M; Khorvash F; Yaran M; Tabarsi P; Dalirrooyfard AH; Motevalli F; Bavand A; Aghakhani A
Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):594-602. PubMed ID: 31080115
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
